Bias in Cardiac AI: Mitigating Risk, Maximizing Returns

AI’s potential in healthcare depends entirely on its equitable application. As we integrate clinical AI into patient care, we’re running headlong into algorithmic bias. This problem, often originating in the very data used to train the models, can amplify existing health disparities, especially in a field as critical as heart failure risk scoring. For academic cardiologists, clinical researchers, and medical directors, tackling this bias isn’t just an intellectual exercise. It’s a professional imperative to ensure our AI serves all patients.

The Unseen Hand: How Algorithms Can Perpetuate Disparity

Any algorithm is only as good as the data it learns from. If the training data is skewed, the model will be biased. It’s that simple. We saw a perfect example of this in Ziad Obermeyer and colleagues’ 2019 Science publication, which showed how a widely used algorithm systematically gave Black patients lower risk scores than White patients with similar health problems. The result? They received less intensive care. This kind of bias creates a dangerous feedback loop where undertreatment based on flawed tech reinforces historical inequities. In heart failure, the consequences are deep. Risk scoring models might rely on variables that are more common or simply better documented in one demographic group over others. It’s a known fact that historical heart failure registries seriously underrepresented people from lower socioeconomic backgrounds, some racial and ethnic minority groups, and women, which means any model trained exclusively on that data is going to perform poorly for those very populations. When an algorithm is trained on data from one demographic, its accuracy will almost certainly drop when applied to another, leading directly to misclassification, delayed diagnoses, or the wrong treatment plan.

Auditing for Equity: Physician Strategies for Identifying Bias

Since we’re the clinicians using these tools, the job of identifying and mitigating bias falls squarely on us. Cardiologists and medical directors have to get proactive and stop just accepting model outputs at face value, instead digging into their mechanics and real-world performance. It starts with understanding exactly how the predictive variables were chosen in the first place. You have to ask the hard questions:

• Data Provenance: Where did the training data come from? Was it a diverse mix of patients that actually represents who I’ll be using this tool on, in terms of race, ethnicity, age, gender, and socioeconomic status?
• Feature Importance: Which variables are actually driving the risk score? And are any of them just proxies for protected characteristics like race or income that could be skewing the predictions?
• Performance Metrics Across Subgroups: How well does this model really perform across different demographic groups? I need to see the sensitivity and specificity broken down by population, because a model with a good overall accuracy score can still be wildly inaccurate for a specific group of my patients.
• External Validation: Has this algorithm been tested on independent, diverse datasets it wasn’t developed with? Real-world evidence (RWE) from multiple clinical settings is what proves a model can be generalized and helps spot biases that didn’t appear during development. We have to demand this level of transparency from AI developers. Any SaMD product in cardiology should come with a strong quality management system (QMS) and follow Good Machine Learning Practice (GMLP) principles.
  

  Advocating for Diverse Datasets and Transparent Development

  Auditing our tools is just one piece. The medical community needs to advocate for systemic changes that lead to more equitable AI development. That means pushing for better, more inclusive data collection and demanding full transparency from vendors. The American Heart Association (AHA) has been very clear about this, and its AHA statements on health equity in digital cardiology stress the need for representative datasets and tough validation. The National Institutes of Health (NIH) is also backing initiatives to make sure research data reflects the actual diversity of the US population, which is the only foundation for building unbiased AI. A practical step is for clinicians to directly engage with developers and demand documentation on the demographic makeup of their datasets. If a vendor won’t provide it, that should be a major concern. We also need to push for including social determinants of health (SDOH) as explicit variables where it’s appropriate and can be done ethically which can help create more equitable models instead of letting SDOH get captured implicitly by biased proxies. The FDA’s guidance on AI/ML is also getting serious about addressing bias. While the FDA isn’t giving out specific percentages for demographic representation, it increasingly expects developers to show exactly how they’ve considered and mitigated bias. For example, a Predetermined Change Control Plan (PCCP) lets an algorithm adapt, but this adaptability has to be managed carefully to prevent algorithmic drift from making biases even worse over time, especially if it isn’t being continuously monitored with diverse real-world data.

  A Path Forward: Collaborative Solutions and Continuous Monitoring

  Dealing with algorithmic bias in heart failure risk scoring is a team sport involving developers, regulators, and clinicians. We physicians are in the clinic, seeing how these tools work in practice. Our insights are what’s needed to identify where the algorithms are failing and guide improvements. Key mitigation strategies include:

• Bias Detection Tools: Using specialized software to find and quantify bias in model outputs across different demographic groups.
• Retraining with Augmented Data: Intentionally adding data from underrepresented groups to training datasets to make the model fairer and more accurate for them.
• Fairness-Aware Machine Learning: Using advanced machine learning methods that build fairness constraints directly into the training process to get equitable performance.
• Human-in-the-Loop Oversight: Always having a human clinician review and, when needed, override the algorithm’s recommendations, particularly for vulnerable populations or when the AI’s confidence score is low. This is the safety net that catches errors before they reach the patient.
• Post-Market Surveillance: Continuously monitoring an algorithm’s performance in real-world clinical use, with a sharp focus on outcomes across diverse patient subgroups. This is how you spot emergent biases or algorithmic drift that weren’t obvious during initial validation. The path to equitable clinical AI is a long one. It requires our vigilance, critical thinking, and a collaborative effort from everyone involved. By getting engaged in the development and oversight of these technologies, academic cardiologists, clinical researchers, and medical directors can make sure AI works to improve health equity. Fairness is good science and good medicine.